Form 4: Neurocrine Biosciences Executive Ingrid Delaet Reports Stock Transactions

Chief Regulatory Officer Ingrid Delaet of Neurocrine Biosciences reported the acquisition and disposition of company stock on May 31, 2024, according to a Form 4 filing.

Summary

• Ingrid Delaet, Chief Regulatory Officer of Neurocrine Biosciences, filed a Form 4 with the SEC.
• On May 31, 2024, Delaet acquired 273 shares of Neurocrine Biosciences common stock at a price of $79.02 per share through the exercise of non-qualified stock options.
• On the same day, Delaet disposed of 273 shares of common stock at a price of $136.55 per share.
• These transactions were executed according to a pre-arranged Rule 10b5-1 trading plan adopted on November 29, 2023.
• Following these transactions, Delaet directly owns 7,507 shares of Neurocrine Biosciences common stock and 4,626 non-qualified stock options.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports routine stock transactions by an executive under a pre-arranged trading plan. There is no indication of positive or negative sentiment towards the company's prospects.

Positives

• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, which can mitigate concerns about insider trading.

Industry Context

Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the trading activities of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.

Comparison to Industry Standards

• Executive stock transactions are common in publicly traded companies, particularly in the biotechnology sector.
• Companies like Amgen, Gilead Sciences, and Biogen also see regular Form 4 filings from their executives.
• The use of Rule 10b5-1 trading plans is a standard practice to allow insiders to sell shares without concerns about insider trading violations.

Key Dates